GSK is experiencing a resurgence in its cancer treatment efforts, with a drug receiving approval for another tumor type and unveiling data from a global study of a promising next-generation chemotherapy. Additionally, a medicine licensed by GSK has gained attention in a presidential session at a major oncology conference, and the company is awaiting another expected approval for a new lung cancer drug in the coming weeks. This positive run for GSK in the oncology field is a testament to the company's efforts and the potential for future success in the treatment of cancer.
Key points
GSK is experiencing a resurgence in its cancer treatment efforts.: GSK is experiencing a resurgence in its cancer treatment efforts.
The company's efforts are paying off as a drug for another tumor type has received approv…: The company's efforts are paying off as a drug for another tumor type has received approval.
GSK has unveiled data from a global study of a promising next-generation chemotherapy.: GSK has unveiled data from a global study of a promising next-generation chemotherapy.
Sources checked by our analysis pipeline: 1
MADRID — In the past week, a GSK cancer drug picked up an approval for another tumor type, the company unveiled the first data from a global study of a promising next-generation chemotherapy, and a medicine that the firm has licensed got the limelight in a presidential session at a major oncology conference here.
GSK is also awaiting another expected approval in the coming weeks, this time for a new lung cancer drug.
It’s a good run considering GSK was out of oncology a decade ago.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
A targeted chemotherapy drug developed by Merck and Kelun-Biotech has significantly reduced the risk of death in patients with advanced endometrial cancer, cutting the risk by one-third according to randomized Phase 3 study results presented at a Madrid conference. This is a common gynecological cancer that has shown survival-extending benefits in studies conducted by Kelun in China, where it’s approved. Merck is conducting 18 global Phase 3 studies of the drug, including 10 studies in women’s cancers, to support…
A toddler died after falling from a terrace while their mother attempted to escape from monkeys in Uttar Pradesh, India. The child was rushed to the hospital but later succumbed to his injuries.
A patient died after receiving Bristol’s investigational CAR-T therapy, and Roche’s lung cancer drug showed promising results in a late-stage study. These developments highlight safety concerns and potential breakthroughs in the rapidly evolving field of cancer treatment.